Overexpression of EZH2 in prostate cancer promotes its progression whereas downregulation of EZH2 inhibits cell proliferation, cell cycle, and invasion in vitro, and tumor reduction in vivo [103]. This evidence concerns the gene EZH2 and prostate carcinoma.